PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Investigational drug reduces heart damage during angioplasty

Anti-inflammatory agent could improve outcomes, reduce costs for heart attack patients

2013-03-12
(Press-News.org) SAN FRANCISCO (March 10, 2013) — A single dose of an investigational anti-inflammatory drug, inclacumab, reduced damage to heart tissue during angioplasty in a study presented today at the American College of Cardiology's 62nd Annual Scientific Session.

More than 1 million coronary angioplasty procedures are performed in the United States each year, at a cost of more than $10 billion. Heart tissue can be damaged during angioplasty, often leading to additional procedures, poor outcomes and higher health care costs.

In this trial, researchers compared a single dose of inclacumab administered one hour before angioplasty with a placebo.

Inclacumab is a human monoclonal antibody that blocks p-selectin, a molecule found in platelets and the cells that line blood vessels. P-selectin is activated in response to inflammation, which can ultimately lead to tissue damage. The study met its primary endpoint: decrease in levels of troponin I, a protein found in the bloodstream when heart damage has occurred, after angioplasty.

"Our hypothesis was that by using the p-selectin antagonist inclacumab, we'd be able to demonstrate vascular benefit," said Jean-Claude Tardif, MD, director of the Research Centre at the Montreal Heart Institute, professor of medicine at the University of Montreal and the study's lead investigator.

The SELECT-acute coronary syndrome phase II trial involved 530 patients with a median age of 61 experiencing a type of heart attack called non-ST-elevation myocardial infarction or NSTEMI. Patients were randomized to receive an infusion of inclacumab at 20 mg/kg, inclacumab at 5 mg/kg or placebo one hour before angioplasty.

Researchers measured heart damage using two standard molecular markers: troponin I and CK-MB. These markers are used clinically to diagnose heart attacks. They were measured at baseline and at eight, 16 and 24 hours after PCI. The co-primary endpoints were the change in troponin I at 16 hours and 24 hours.

In patients receiving 20 mg/kg of inclacumab, troponin I levels dropped 22.4 percent more at 16 hours (p=0.066) and 24.4 percent more at 24 hours (p=0.05), compared with patients on placebo. CK-MB levels dropped 16.3 percent more at 16 hours (p=0.088) and 17.4 percent more at 24 hours (p=0.055), compared with patients on placebo.

Also, at 24 hours after angioplasty, 18.3 percent of patients on placebo had CK-MB increases of more than three times the upper limit of normal, a threshold that many clinical trials use to define a post-angioplasty heart attack. This compared with 8.9 percent of patients who received the higher dose of inclacumab (p=0.051).

The 5 mg/kg dose of inclacumab had no significant effects on the cardiac markers. Researchers also measured p-selectin levels to see if they correlated with changes in CK-MB and troponin I. Levels did not drop significantly in the group that received 5 mg/kg inclacumab. However, levels dropped 19.2 percent with the 20 mg/kg inclacumab dose, compared with placebo (p=0.0002).

"It was exciting to see that a single administration of inclacumab would yield clinical benefit," Dr. Tardif said.

The researchers analyzed a subgroup of patients who were not taking antiplatelet drugs called glycoprotein 2b3a inhibitors. These are given to some patients to prevent blood clots but can increase the risk of bleeding. In patients not taking 2b3a inhibitors, those who received the 20 mg/kg dose of inclacumab experienced a 36 percent decrease in troponin I at 24 hours (p=0.008 compared with placebo).

"If we're able to confirm these results in potential future studies, this drug could become part of the therapeutic armamentarium in modern cardiology," Dr. Tardif said. "You could use this drug more widely, in all patients coming in with heart attacks, although that would require additional large studies."

###The trial was sponsored by Hoffman-La Roche, Ltd. Dr. Tardif's institution has received financial support from Hoffman-La Roche.

The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC13 for the latest news from the meeting.

The American College of Cardiology is a nonprofit medical society comprised of 43,000 physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is dedicated to transforming cardiovascular care, improving heart health and advancing quality improvement, patient-centered care, payment innovation and professionalism. The ACC also leads the formulation of important cardiovascular health policy, standards and guidelines. It bestows credentials upon cardiovascular specialists, provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality care. For more information, visit cardiosource.org.

Dr. Tardif will be available to the media on Sunday, March 10 at 12:30 p.m., in Moscone Center, South, Room 300.

Dr. Tardif will present the study "Effects of the P-Selectin Antagonist Inclacumab in the Select-Acute Coronary Syndromes Trial" on Sunday, March 10 at 11:21 a.m., in Moscone Center, South, Esplanade Ballroom.

Media Contacts
Beth Casteel
240-328-4549
bcasteel@acc.org

Nick Mitsis
703-951-3589
acc@ecius.net

ACC.13 News Room
415-978-3511


ELSE PRESS RELEASES FROM THIS DATE:

Clot-busting drug as effective as angioplasty

2013-03-12
SAN FRANCISCO (March 10, 2013) — A clot-busting therapy may benefit some heart attack patients who cannot have immediate angioplasty, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. "Drug therapy before transfer is at least as effective as [angioplasty], and an urgent catheterization was avoided in two-thirds of patients," said Frans Van de Werf, MD, PhD, professor of cardiology at University of Leuven, Belgium, and the study's lead investigator. "It gives [clinicians] time to consider other options, such ...

Drug reduces chest pain in patients with diabetes

2013-03-12
SAN FRANCISCO (March 10, 2013) — A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. Ranolazine is approved by the U.S. Food and Drug Administration for the treatment of chronic angina, or chest pain, both as first line therapy and as an add-on when symptoms are not relieved with other anti-anginal drugs, including beta-blockers, calcium channel ...

High-dose oral vitamins, minerals do not reduce recurrent cardiac events in heart attack patients

2013-03-12
SAN FRANCISCO (March 10, 2013) — Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. However, the results of one component of the NIH-funded Trial to Assess Chelation Therapy (TACT) study, shows that when combined with active chelation therapy, high-dose vitamins and minerals may provide some additional benefit. The TACT study tested the safety and effectiveness of ...

Digoxin reduces hospital admissions in older patients with chronic heart failure

2013-03-12
SAN FRANCISCO (March 11, 2013) —Digoxin significantly reduces the likelihood of hospital admission due to all causes among ambulatory older patients with chronic heart failure and reduced ejection fraction (HFrEF), according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. Researchers reviewed patient outcomes from 1995 in the Digitalis Investigation Group (DIG) trial of 6,800 patients with HFrEF—a condition in which the heart is too weak to pump and patients suffer from breathlessness and fatigue. Patients with HFrEF ...

Clot-busting drug benefits intermediate-risk patients with pulmonary embolism

2013-03-12
SAN FRANCISCO (March 11, 2013) — The clot-busting drug tenecteplase prevents death or circulatory collapse in a subgroup of patients with a blood clot in the lungs and appears to be especially useful in patients younger than 75, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. Pulmonary embolism occurs when part of a blood clot in a vein breaks off and travels to the lungs. It is fatal about 10 percent of the time, killing between 60,000 and 100,000 Americans each year. The most common cause of death is progressive ...

Screenings, targeted care reduce heart failure in at-risk patients

2013-03-12
SAN FRANCISCO (March 11, 2013) — For at-risk patients, a simple screening and management program can be effective in preventing heart failure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. The five-year STOP-HF study enrolled asymptomatic patients over 40 years of age with risk factors for heart failure and randomized them into an intervention and a control group. Patients in the intervention group were screened for blood levels of B-type natriuretic peptide (BNP), a hormone that indicates how well the heart ...

No benefit found from BP drug in treatment of recently hospitalized heart failure patients

2013-03-12
SAN FRANCISCO (March 11, 2013) —Despite high hopes that a blood pressure-lowering medication called aliskiren would help people following hospitalization for heart failure, no beneficial effects were found, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. Heart failure is the leading cause of hospitalization for people over age 65, costing Medicare billions of dollars annually, and researchers are always on the lookout for more effective treatments. The Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) ...

Erectile dysfunction drug fails for diastolic heart failure patients

2013-03-12
SAN FRANCISCO (March 11, 2013) — Despite high expectations for a commonly used erectile dysfunction drug to treat patients with diastolic heart failure, no beneficial effects were found in a study presented today at the American College of Cardiology's 62nd Annual Scientific Session. The RELAX Study is the first multicenter trial to look at the effect of chronic therapy with sildenafil in diastolic heart failure. Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor, a class of drugs used to treat erectile dysfunction and certain types of pulmonary arterial hypertension. ...

Low T3 syndrome predicts unfavorable outcomes in surgical patients with brain tumor

2013-03-12
Charlottesville, VA (March 12, 2013). In a study of 90 patients undergoing surgery for brain tumor, researchers in Lithuania (Lithuanian University of Health Sciences) and the United States (University of North Carolina at Chapel Hill and Brigham & Women's Hospital, Harvard University) have discovered that the finding of low T3 (triiodothyronine) syndrome is predictive of unfavorable clinical outcomes and depressive symptoms. Details of this study are furnished in the article "Low triiodothyronine syndrome as a predictor of poor outcomes in patients undergoing brain tumor ...

What impact does a day of roller derby have on our skin microbiome?

2013-03-12
The human skin is home to countless microorganisms that we can't see, but these microbes help define who we are. Our invisible passengers – known as the skin microbiome - contribute to our health in numerous ways including educating our immune system, protecting us from pathogens, and mediating skin disorders. In a new study, researchers investigated how the skin microbiome is transmitted between players in a contact sport, using roller derby as their model system. The skin is the largest organ and an important barrier that regulates microbial entry into the human body. ...

LAST 30 PRESS RELEASES:

Exercise as an anti-ageing intervention to avoid detrimental impact of mental fatigue

UMass Amherst Nursing Professor Emerita honored as ‘Living Legend’

New guidelines aim to improve cystic fibrosis screening

Picky eaters by day, buffet by night: Butterfly, moth diets sync to plant aromas

Pennington Biomedical’s Dr. Leanne Redman honored with the E. V. McCollum Award from the American Society for Nutrition

CCNY physicists uncover electronic interactions mediated via spin waves

Researchers’ 3D-printing formula may transform future of foam

Nurture more important than nature for robotic hand

Drug-delivering aptamers target leukemia stem cells for one-two knockout punch

New study finds that over 95% of sponsored influencer posts on Twitter were not disclosed

New sea grant report helps great lakes fish farmers navigate aquaculture regulations

Strain “trick” improves perovskite solar cells’ efficiency

How GPS helps older drivers stay on the roads

Estrogen and progesterone stimulate the body to make opioids

Dancing with the cells – how acoustically levitating a diamond led to a breakthrough in biotech automation

Machine learning helps construct an evolutionary timeline of bacteria

Cellular regulator of mRNA vaccine revealed... offering new therapeutic options

Animal behavioral diversity at risk in the face of declining biodiversity

Finding their way: GPS ignites independence in older adult drivers

Antibiotic resistance among key bacterial species plateaus over time

‘Some insects are declining but what’s happening to the other 99%?’

Powerful new software platform could reshape biomedical research by making data analysis more accessible

Revealing capillaries and cells in living organs with ultrasound

American College of Physicians awards $260,000 in grants to address equity challenges in obesity care

Researchers from MARE ULisboa discover that the European catfish, an invasive species in Portugal, has a prolonged breeding season, enhancing its invasive potential

Rakesh K. Jain, PhD, FAACR, honored with the 2025 AACR Award for Lifetime Achievement in Cancer Research

Solar cells made of moon dust could power future space exploration

Deporting immigrants may further shrink the health care workforce

Border region emergency medical services in migrant emergency care

Resident physician intentions regarding unionization

[Press-News.org] Investigational drug reduces heart damage during angioplasty
Anti-inflammatory agent could improve outcomes, reduce costs for heart attack patients